Sarah Hymowitz is a venture capital investor at The Column Group who spent 22 years at Genentech rising to Vice President of Protein Sciences, where she oversaw the development of more than 35 large-molecule clinical candidates and played a leading role in discovering Venclexta, a first-in-class cancer drug. Her unusually deep hands-on drug discovery experience, combined with her PhD in Biophysics from UCSF, gives her a rare scientific background among venture investors focused on biotech company formation.